

Special Issue

Pharmaceutical Research in Stem Cells

Message from the Guest Editor

Stem-cell-based therapy has become a hot spot in the biomedical field. In past decades, scientists focused on the development of stem cell products for investigational new drug (IND) studies. Many types of stem cell drugs have entered the stage of clinical trials, including functional cells derived from adult stem cells and pluripotent stem cells. Basic studies and clinical trials have demonstrated the evident efficacy of stem-cell therapy in several diseases. Still, a great deal of work remains for the future, from first- to second-generation stem-cell therapies and advancing to next-generation therapies through engineering approaches to improve their function and efficacy or broaden the scope of their clinical application to new indications. Understanding the safety and efficacy, heterogeneity, in vivo fate and distribution of stem cells are the prerequisites for the clinical translation of this technology. This Special Issue will collect related research on the pharmaceutical research of stem cell products in various forms, including case studies, reports, reviews, and original research articles.

Guest Editor

Dr. Wenwen Jia

School of Life Sciences and Technology, Tongji University, Shanghai 200092, China

Deadline for manuscript submissions

closed (25 June 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/117457

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/

[genes](https://genes.mdpi.com)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))